New Monograph Describes Racial/Ethnic Cancer Patterns in the US

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

BETHESDA, Md--Newly available from the NIH/NCI (NIH Publication 96-4104, April 1996) is a SEER monograph entitled Racial/Ethnic Patterns of Cancer in the United States, 1988-1992.

BETHESDA, Md--Newly available from the NIH/NCI (NIH Publication96-4104, April 1996) is a SEER monograph entitled Racial/EthnicPatterns of Cancer in the United States, 1988-1992.

"This landmark report presents the most extensive informationyet available on racial and ethnic differences in cancer experience,"said Edward Sondik, PhD, deputy director of the NCI's Divisionof Cancer Prevention and Control, which prepared the publication."It cannot be overstated as to how important these data willbe to our understanding of cancer."

Articles in this issue
Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down
Pain Scale Resembling Thermometer May Be Easier to Use Than VAS
Immediate Hormone Therapy Improves Prostate Cancer Survival
New Test for Prostate Cancer Risk
Topotecan: Significant Activity in Ovarian Cancer
Prostate Cancer Guideline Classifies Patients By Risk Status
New Monograph Describes Racial/Ethnic Cancer Patterns in the US
Moral Challenges Ahead as Managed Care Marches On
One Doctor Tells His Experience With Hospital Mergers
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.